December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

628.94 +5.51 (+0.88%)
Streaming Delayed Price Updated: 10:44 AM EDT, Jun 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
63 64 Next >
News headline image
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years ↗
 
Via Benzinga
News headline image
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Discover the top S&P500 movers in Wednesday's pre-market session. ↗
Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top S&P500 gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
ROSEN, A LEADING LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
How Databricks Pounced On AI Opportunity Amid Snowflake, Palantir Rivalries ↗
The rivalry between enterprise software makers Snowflake and Databricks intensified amid the emergence of generative artificial intelligence. 
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Healthcare And Biotech Playbook As Disruption Gathers Force ↗
The XBI was down 1.54% for the week, like off a cliff on Friday from a Wednesday high of $94.82. 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study ↗
4D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements. 
Via Benzinga
News headline image
Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move ↗
Via The Motley Fool
News headline image
Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings tomorrow before the bell. Here’s what to expect. 
Via StockStory
News headline image
EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting
EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4... 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 8 ↗
What has Wall Street been buzzing about this week? Here is a look at the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Feb. 3-7, 2025. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years ↗
 
Via Benzinga
News headline image
Regeneron Stock Down 30% Over Past 6 Months: Leerink Sees Buying Opportunity, Retail's On The Same Page ↗
The analyst sees 2025 as a challenging year due to Eylea headwinds but expects growth to accelerate in 2026, driven by strong eczema treatment sales from the company’s Dupixent drug. 
Via Stocktwits
News headline image
Billions in Buybacks: 4 Stocks Rewarding Shareholders Now
These stocks are looking to return varying amounts of capital to shareholders using buybacks. One fintech's buyback capacity is equal to 25% of its market cap. 
Via MarketBeat
News headline image
Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains. ↗
The company won three FDA approvals over the past two years. Now, it's angling for two new approvals in 2025. 
Via Investor's Business Daily
News headline image
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday ↗
Via The Motley Fool
News headline image
Uncover the latest developments among S&P500 stocks in today's session. ↗
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
News headline image
Discover which S&P500 stocks are making waves on Tuesday. ↗
Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session. 
Via Chartmill
News headline image
Regeneron Pharma Q4 Earnings Crush Estimates, Initiates Dividend And Additional Stock Buyback Program ↗
Regeneron beat Q4 estimates with $12.07 EPS and $3.79B in sales. The company announced a dividend, a $3 billion buyback, and continued R&D investments. 
Via Benzinga
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
US Stocks Rise Despite China's Trade Fears, Palantir Defies Gravity, Gold Rallies Further: What's Driving Markets Tuesday? ↗
U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the world’s two largest economies. 
Via Benzinga
News headline image
Regeneron Advances On Fourth-Quarter Beat As Eylea Meets Expectations ↗
Regeneron stock rose early Tuesday on a strong fourth-quarter report that included in-line sales of eye drug Eylea. 
Via Investor's Business Daily
News headline image
Regeneron’s (NASDAQ:REGN) Q4 Sales Top Estimates, Stock Soars
Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 per share... 
Via StockStory
News headline image
Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to ~$4.5 Billion
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Earnings Scheduled For February 4, 2025 ↗
 
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
63 64 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.